DoW Breast Cancer, Clinical Research Extension Award

In plain English

Defense Health Agency Contracting Activity - DHACA (Department of Defense) is accepting applications for this grant until Nov 18, 2026 (7 days left).

The agency expects to make 1 award and estimated total program funding is $8,400,000.

Eligibility is listed as unrestricted (open to any type of applicant), subject to any clarification in the listing.

The listing says cost sharing or matching is not required.

Built only from the fields in the Grants.gov listing. Always confirm on the official listing.

• Unrestricted (open to any type of entity above, subject to clarification in the listing)

Excerpt from the official synopsis on Grants.gov (shortened; read the full text on the official listing):

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Distinctive Features: • The research team must include two or more breast cancer consumer advocates. • This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. …

Read the full listing on Grants.gov →